Caspase Cleavage of Gene Products Associated with Triplet Expansion Disorders Generates Truncated Fragments Containing the Polyglutamine Tract*

The neurodegenerative diseases Huntington disease, dentatorubropallidoluysian atrophy, spinocerebellar atrophy type 3, and spinal bulbar muscular atrophy are caused by expansion of a polyglutamine tract within their respective gene products. There is increasing evidence that generation of truncated proteins containing an expanded polyglutamine tract may be a key step in the pathogenesis of these disorders. We now report that, similar to huntingtin, atrophin-1, ataxin-3, and the androgen receptor are cleaved in apoptotic extracts. Furthermore, each of these proteins is cleaved by one or more purified caspases, cysteine proteases involved in apoptotic death. The CAG length does not modulate susceptibility to cleavage of any of the full-length proteins. Our results suggest that by generation of truncated polyglutamine-containing proteins, caspase cleavage may represent a common step in the pathogenesis of each of these neurodegenerative diseases.

[1]  M. Nance.  Clinical Aspects of CAG Repeat Diseases , 1997, Brain pathology.

[2]  M. Dragunow,et al.  In situ evidence for DNA fragmentation in Huntington's disease striatum and Alzheimer's disease temporal lobes , 1995, Neuroreport.

[3]  S. W. Davies,et al.  Exon 1 of the HD Gene with an Expanded CAG Repeat Is Sufficient to Cause a Progressive Neurological Phenotype in Transgenic Mice , 1996, Cell.

[4]  C. Ross,et al.  Huntington's Disease and Dentatorubral‐Pallidoluysian Atrophy: Proteins, Pathogenesis and Pathology , 1997, Brain pathology.

[5]  R. Tanzi,et al.  Alternative cleavage of Alzheimer-associated presenilins during apoptosis by a caspase-3 family protease. , 1997, Science.

[6]  S. Tsuji,et al.  Suppression of aggregate formation and apoptosis by transglutaminase inhibitors in cells expressing truncated DRPLA protein with an expanded polyglutamine stretch , 1998, Nature Genetics.

[7]  N. Thornberry,et al.  A combinatorial approach for determining protease specificities: application to interleukin-1beta converting enzyme (ICE). , 1997, Chemistry & biology.

[8]  A. Kakizuka.  Degenerative ataxias: genetics, pathogenesis and animal models. , 1997, Current opinion in neurology.

[9]  D. Nicholson.  ICE/CED3-like Proteases as Therapeutic Targets for the Control of Inappropriate Apoptosis , 1996, Nature Biotechnology.

[10]  M. Hayden,et al.  Of molecular interactions, mice and mechanisms: new insights into Huntington's disease. , 1997, Current opinion in neurology.

[11]  N. Thornberry,et al.  A Combinatorial Approach Defines Specificities of Members of the Caspase Family and Granzyme B , 1997, The Journal of Biological Chemistry.

[12]  M. Hayden,et al.  Rethinking genotype and phenotype correlations in polyglutamine expansion disorders. , 1997, Human molecular genetics.

[13]  Í. Lopes-Cendes,et al.  The Neuropathology of CAG Repeat Diseases: Review and Update of Genetic and Molecular Features , 1997, Brain pathology.

[14]  H. Loetscher,et al.  Presenilins Are Processed by Caspase-type Proteases* , 1997, The Journal of Biological Chemistry.

[15]  Y. Agid,et al.  Cloning of the SCA7 gene reveals a highly unstable CAG repeat expansion , 1997, Nature Genetics.

[16]  S. W. Davies,et al.  Aggregation of huntingtin in neuronal intranuclear inclusions and dystrophic neurites in brain. , 1997, Science.

[17]  L Pinsky,et al.  Evidence for a repressive function of the long polyglutamine tract in the human androgen receptor: possible pathogenetic relevance for the (CAG)n-expanded neuronopathies. , 1995, Human molecular genetics.

[18]  J. O’Kusky,et al.  Toward Understanding the Molecular Pathology of Huntington's Disease , 1997, Brain pathology.

[19]  J. Hodgson,et al.  Huntingtin Is Ubiquitinated and Interacts with a Specific Ubiquitin-conjugating Enzyme* , 1996, The Journal of Biological Chemistry.

[20]  H. Horvitz,et al.  Genetic control of programmed cell death in the nematode C. elegans , 1986, Cell.

[21]  K. Fischbeck,et al.  Intranuclear Inclusions of Expanded Polyglutamine Protein in Spinocerebellar Ataxia Type 3 , 1997, Neuron.

[22]  J. O’Kusky,et al.  Absence of disease phenotype and intergenerational stability of the CAG repeat in transgenic mice expressing the human Huntington disease transcript. , 1996, Human molecular genetics.

[23]  Mark Turmaine,et al.  Formation of Neuronal Intranuclear Inclusions Underlies the Neurological Dysfunction in Mice Transgenic for the HD Mutation , 1997, Cell.

[24]  G. Salvesen,et al.  The Regulation of Anoikis: MEKK-1 Activation Requires Cleavage by Caspases , 1997, Cell.

[25]  Seamus J. Martin,et al.  Protease activation during apoptosis: Death by a thousand cuts? , 1995, Cell.

[26]  Patrick R. Griffin,et al.  Identification and inhibition of the ICE/CED-3 protease necessary for mammalian apoptosis , 1995, Nature.

[27]  M. Hayden,et al.  Cleavage of huntingtin by apopain, a proapoptotic cysteine protease, is modulated by the polyglutamine tract , 1996, Nature Genetics.

[28]  A. Porter,et al.  Death substrates come alive , 1997, BioEssays : news and reviews in molecular, cellular and developmental biology.

[29]  N. Thornberry,et al.  The three-dimensional structure of apopain/CPP32, a key mediator of apoptosis , 1996, Nature Structural Biology.

[30]  C A Ross,et al.  When more is less: Pathogenesis of glutamine repeat neurodegenerative diseases , 1995, Neuron.

[31]  S. Narumiya,et al.  Expanded polyglutamine in the Machado–Joseph disease protein induces cell death in vitro and in vivo , 1996, Nature Genetics.

[32]  C. Ross,et al.  DRPLA gene (atrophin-1) sequence and mRNA expression in human brain. , 1996, Brain research. Molecular brain research.

[33]  G. Salvesen,et al.  Target Protease Specificity of the Viral Serpin CrmA , 1997, The Journal of Biological Chemistry.

[34]  R. Tjian,et al.  Functional domains and upstream activation properties of cloned human TATA binding protein. , 1990, Science.

[35]  H. Zoghbi,et al.  The CAG/Polyglutamine Tract Diseases: Gene Products and Molecular Pathogenesis , 1997, Brain pathology.